Chronic Lymphocytic Leukemia | Specialty

Novel BTK Inhibitors and Combos May Hold the Key to B-Cell Malignancies

May 21st 2015

Combination therapy has significant potential to fill the niche of developing resistance to BTK inhibitors and rational pairings of ibrutinib with other standard treatments, including chemoimmunotherapy and CD20-targeting monoclonal antibodies (mAbs) are rapidly gaining ground.

Siteman Cancer Center Houses Broad Research Program

May 15th 2015

Venetoclax Breakthrough Designation, Zarxio Legal Update, and More

May 15th 2015

Dr. Lamanna on Incorporating Novel and Traditional Therapies in CLL

May 15th 2015

Nicole Lamanna, MD, Associate Professor of Clinical Medicine, Columbia University Medical Center, discusses incorporating novel therapies into the standard treatment paradigm for patients with chronic lymphocytic leukemia (CLL).

FDA Grants Venetoclax Breakthrough Designation for CLL

May 7th 2015

The FDA has granted a breakthrough therapy designation to the Bcl-2 inhibitor venetoclax (GDC-0199/ABT-199) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who harbor a 17p deletion (del[17p]).

Ibrutinib and Idelalisib Continue to Impress in CLL, May Eventually Replace Chemotherapy for Some Patients

April 28th 2015

To gain further insight into the impact of ibrutinib and idelalisib, as well as other emerging therapies and treatment strategies in CLL, OncLive sat down with Steven Coutre, MD, at the AACR meeting,

Dr. Steven Coutre on the Eventual Role of Chemotherapy in CLL

April 28th 2015

Steven Coutre, MD, professor of medicine, Stanford University Medical Center, discusses the eventual role chemotherapy will have in the treatment of chronic lymphocytic leukemia.

Ofatumumab/Chemo Combination Delays Progression in CLL

April 27th 2015

Treatment with ofatumumab plus fludarabine and cyclophosphamide significantly improved progression-free survival compared with fludarabine and cyclophosphamide alone in patients with relapsed chronic lymphocytic leukemia.

Ibrutinib Response Rates Improve With Longer Follow-Up in CLL

April 24th 2015

Single-agent ibrutinib demonstrated an overall response rate of 91%, including a complete response rate of 14%, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Costly New Drugs Could Lead to Generation of Have-Nots in CLL

March 26th 2015

Ibrutinib and idelalisib will increase individual out-of-pocket and societal costs of caring for patients with CLL.

Role of Chemotherapy in CLL Shifts as Novel Agents Transform Clinical Practice

March 26th 2015

In an interview with OncLive, William G. Wierda, MD, PhD, discusses the changing role of chemotherapy in the management of CLL and the integration of novel agents into clinical practice.

Potential Ibrutinib Resistance Mechanisms Identified in CLL

March 20th 2015

Progression on treatment with ibrutinib in patients with chronic lymphocytic leukemia was associated with pretreatment BCL6 abnormalities, acquired mutations in BTK and PLCG2, and complex karyotypes.

Dr. Wierda on RESONATE-2 Trial Predictions for Patients With CLL

March 20th 2015

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center in Houston, discusses upcoming RESONATE-2 trial results for patients with chronic lymphocytic leukemia (CLL).

Ibrutinib Regimen Extends PFS in Phase III CLL Study

March 17th 2015

The phase III HELIOS study examining ibrutinib in combination with bendamustine and rituximab has been unblinded following the demonstration of a significant extension in progression-free survival in patients with CLL or SLL.

AbbVie Gains Ibrutinib Through Pharmacyclics Acquisition

March 5th 2015

AbbVie has announced plans to acquire the blockbuster BTK inhibitor ibrutinib, through a $21 billion acquisition of Pharmacyclics.

New Approvals Transform CLL Treatment, More Advances on the Horizon

February 25th 2015

For additional insight on new agents and other emerging CLL therapies, OncLive spoke with Thomas Kipps, MD, PhD, professor of Medicine in the Division of Hematology-Oncology, and Deputy Director for Research at the UC San Diego Moores Cancer Center.

Dr. Kipps on Ibrutinib and Idelalisib For CLL

February 25th 2015

Thomas Kipps, MD, PhD, Division of Hematology-Oncology Deputy Director for Research at the UC San Diego Moores Cancer Center, discusses the mechanisms of ibrutinib and idelalisib for the treatment of chronic lymphocytic leukemia (CLL).

Integration of Novel CLL Agents Into Frontline Setting Continues to Evolve

February 21st 2015

Jeffrey Jones, MD, presented evidence supporting the integration of obinutuzumab, ibrutinib, ofatumumab, and idelalisib into the frontline setting for patients with chronic lymphocytic leukemia.

Chemotherapy for CLL Not Yet Obsolete But in Flux as New Agents Gain Ground

February 21st 2015

Standard chemotherapy remains part of the treatment paradigm for patients with chronic lymphocytic leukemia but its role is undergoing a major shift as significant advances are being made in novel therapies.

ASCO Selects Dramatic Improvement in CLL Care as 'Cancer Advance of the Year'

January 20th 2015

ASCO named the vastly improved outlook for patients with chronic lymphocytic leukemia as its inaugural "Cancer Advance of the Year."